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The inhibition of Bid expression by Akt leads to resistance
to TRAIL-induced apoptosis in ovarian cancer cells
N Goncharenko-Khaider, D Lane, I Matte, C Rancourt and A Piche ´
De ´partement de Microbiologie et Infectiologie, Faculte ´ de Me ´decine, Universite ´ de Sherbrooke, Sherbrooke, Canada
Epithelial ovarian cancer (EOC) cells often show
increased activity of the PI3K/Akt pathway. In addition,
we have previously shown that EOC ascites induce Akt
activation in the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL)-sensitive EOC cell line, CaOV3,
leading to TRAIL-mediated apoptosis inhibition. In this
study, we investigated the role of Akt in intrinsic
resistance to TRAIL, which is common in EOC cells.
We report that Akt activation reduces the sensitivity of
EOC cells to TRAIL. TRAIL-resistant SKOV3ip1 and
COV2 cells were sensitized to TRAIL-induced apoptosis
by PI3K or Akt inhibitors although inhibition of PI3K/
Akt signaling pathway did not interfere with the recruit-
ment and processing of caspase-8 to the death-inducing
signaling complex. Conversely, overexpression of Akt1 in
TRAIL-sensitive cells promoted resistance to TRAIL.
Although the fact that TRAIL-induced caspase-8 activa-
tion was observed in both sensitive and resistant cell lines,
Bid cleavage occurred only in sensitive cells or in
SKOV3ip1 cells treated with LY294002. Bid expression
was low in resistant cells and Akt activation down-
regulated its expression. Depletion of Bid by siRNA in
OVCAR3 cells was associated with a decrease in TRAIL-
mediated apoptosis. Overexpression of Bid only in SKOV3ip1
cells enhanced TRAIL-induced apoptosis. Simultaneous
blockade of Akt pathway further increased TRAIL-induced
apoptosis. Thus, Akt acts upstream of mitochondria and
inhibits TRAIL-induced apoptosis by decreasing Bid protein
levels and possibly inhibiting its cleavage.
Oncogene (2010) 29, 5523–5536; doi:10.1038/onc.2010.288;
published online 26 July 2010
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Introduction
Resistance to chemotherapy is a major problem in
epithelial ovarian cancer (EOC) treatment. Despite
initial high response rate in patients with advanced
EOC, most patients relapse with tumor that acquires
resistance to chemotherapy (Yap et al., 2009). The
tumor necrosis factor related-apoptosis-inducing ligand
(TRAIL) holds great promise as an anti-cancer therapy
because of its selective apoptosis-inducing action on
tumor cells vs normal cells (Newsom-Davis et al., 2009).
TRAIL-based therapies are now in phase I/II clinical
trials (http://www.clinicaltrials.gov). TRAIL resistance
in tumor cells, including EOC, may limit its therapeutic
use (LeBlanc et al., 2002; Lane et al., 2004; Zhang and
Fang, 2005). On binding to its receptors DR4 (TRAIL-
R1) and DR5 (TRAIL-R2) TRAIL induces the forma-
tion of the death-inducing signaling complex (DISC) by
recruiting Fas-associated death domain. Fas-associated
death domain through its death effector domain recruits
caspases-8/10, which assemble into the DISC (Kischkel
et al., 1995; Bodmer et al., 2000). When recruited to the
DISC, pro-caspases-8 is activated through proteolytic
cleavage, resulting in active caspase-8 that may directly
cleave downstream effector caspases (caspase-3, -6
and -7) leading to apoptosis. Alternatively, caspase-8
cleaves the BH3 domain-containing protein Bid, to
generate a pro-apoptotic truncated form (tBid), which
translocates to the mitochondrial membrane and trig-
gers the intrinsic apoptosis pathway.
Although there are a number of means by which the
association between TRAIL signaling cascade and the
apoptotic machinery could be altered in TRAIL-resistant
EOC cells, the phosphatidylinositol-3-kinase (PI3K)/Akt
pathway is of particular interest because it is an important
determinant of oncogenic transformation in EOC. The
PI3K/Akt pathway is activated in a signiﬁcant number of
EOC cells (B70%) because of ampliﬁcation/overexpres-
sion/mutation (Bast et al., 2009). Activation of the PI3K/
Akt pathway was shown to have a role in protecting EOC
cells from chemotherapy-induced apoptosis (Page et al.,
2000; Hu et al., 2002; Yang et al., 2006). Drugs and death
receptor ligands rely on activation of apoptotic signaling
pathways to destroy tumor cells. Indeed, the resistance to
chemotherapy is because of the failure of tumor cells to
undergo apoptosis. As shown by us and others, death
receptor-mediated apoptosis is deﬁcient in nearly 50% of
ovarian cancer cell lines and primary tumors (Lane et al.,
2004). Consequently, to fully exploit the potential of
TRAIL, the problem of TRAIL resistance in EOC cells
must be ﬁrst understood.
Akt activation was shown to protect against TRAIL-
induced apoptosis in several cell types, including
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www.nature.com/oncmelanomas and prostate, ovarian and non-small cell
lung cancers (Chen et al., 2001; Nesterov et al., 2001;
Kandasamy and Srivastava, 2002; Larribere et al., 2004;
Kim and Lee, 2007; Lane et al., 2007). However, there
are conﬂicting reports about the mechanisms by which
Akt exerts its protective effect. In non-small cell lung
and prostate cancer, Akt activation inhibited TRAIL-
induced apoptosis by interfering with Bid cleavage by
means of an unknown mechanism (Chen et al., 2001;
Nesterov et al., 2001; Kandasamy and Srivastava, 2002).
Inhibition of PI3K or AKT, completely blocked the
anti-apoptotic effect of stem cell factor on TRAIL-
induced apoptosis in melanoma cells (Larribere et al.,
2004). FLIP did not appear to be involved but the
precise mechanism was unclear. In TRAIL-sensitive
EOC cells, inhibition of PI3K and Akt substantially
inhibited the pro-survival effect of EOC ascites by
a mechanism that involved upregulation of c-FLIPs
(Lane et al., 2007).
Previous studies have shown that EOC cell suscept-
ibility to TRAIL cannot be explained by the levels of
TRAIL receptors (Cuello et al., 2001; Siervo-Sassi et al.,
2003; Lane et al., 2004). TRAIL induces mitochondria-
dependent apoptosis in EOC, a characteristic of the type
II cells (Cuello et al., 2004). Bid has a central role in type
II cells by connecting the mitochondria pathway of
apoptosis to the extrinsic pathway (Newsom-Davis
et al., 2009). Akt regulates the activity of Bad, Bax
and X-linked inhibitor of apoptosis (XIAP) to promote
survival (Datta et al., 1997; del Peso et al., 1997;
Kandel and Hay, 1999; Dan et al., 2004). Akt may also
upregulate the expression of anti-apoptotic proteins
such as Bcl-2 (Du and Montminy, 1998). However, a
recent study has shown that Akt activation does not
affect the expression of Bcl-2, Bcl-XL and Bax (Lane
et al., 2007). Thus, the mechanisms by which Akt
confers protection and its action on the mitochondrial
pathway in TRAIL-induced apoptosis remains to be
fully understood in EOC cells.
In this study, we have examined the role of Akt
and the mechanism of intrinsic TRAIL resistance
in ovarian cancer cells. We report for the ﬁrst time
that Akt activation inhibits TRAIL-induced apop-
tosis by decreasing Bid expression. Furthermore, Bid
depletion by RNA interference led to a decrease
of TRAIL-induced apoptosis. These results show
that Akt acts upstream of the mitochondria at the
Bid level to inhibit TRAIL-induced cell death in
EOC cells.
Results
TRAIL resistance is associated with Akt activation
in EOC cells
We have previously shown that ascites-mediated Akt
activation protects CaOV3 cells against TRAIL-induced
apoptosis (Lane et al., 2007). In addition, we showed
that cell detachment decreased Akt activity and sensi-
tized SKOV3ip1 and COV2 EOC cells to TRAIL (Lane
et al., 2008). These data suggest that Akt may be an
important regulator of TRAIL-induced apoptosis. In this
study, we investigated whether Akt is indeed a mediator
of TRAIL resistance. For our studies, four EOC cell
lines were used. The cell lines were subdivided into
sensitive (o20% cell viability; CaOV3 and OVCAR3
cells) and resistant (80% cell viability; COV2 and
SKVO3ip1 cells) to TRAIL-induced cell death (Figure 1a).
In sensitive cells, TRAIL treatment decreased the number
of colonies by 10-fold whereas the number of colonies
remained mostly unchanged in resistant cells (Figure 1b).
TRAIL-induced apoptosis was signiﬁcantly greater in
sensitive cells when compared with COV2 and SKOV3ip1
cells as measured by oligosomal DNA fragmentation
(Figure 1c) and the percentage of hypodiploid cells
(Figure 1d).
We examined the basal level of phospho-Akt in our
panel of cell lines. As shown in Figure 1e, there was a
positive correlation between high levels of Akt phos-
phorylation and resistance to TRAIL. Interestingly,
however, there was no correlation between levels of
c-FLIPS or c-FLIPL proteins, which inhibit caspase-8
activation at the DISC (Kruger et al., 2001; Panka et al.,
2001; Panner et al., 2005), and the sensitivity of EOC
cell lines to TRAIL-induced apoptosis.
Overexpression of Akt1 inhibits TRAIL-induced
apoptosis in CaOV3 cells
We determined whether Akt1 overexpression would
exert a protective effect against TRAIL-induced apop-
tosis. CaOV3 cells overexpressing Akt1 (CaOV3-Akt-1
(wt)) or vector-transfected cells (CaOV3 (vector)) were
validated by immunoblot (Figure 2a). Of note, the
ectopic expression of Akt1 did not affect the protein
levels of FLIPL and FLIPS (data not shown). CaOV3-
Akt1 (wt) cells were signiﬁcantly (Po0.001) more
resistant to TRAIL compared with CaOV3 (vector)
cells as indicated by a dose-response curve (Figure 2b)
and colony formation after TRAIL exposure (20ng/ml)
(Figure 2c). However, the resistance of CaOV3-Akt1
(wt) cells can be overcome by higher concentrations
of TRAIL (Figure 2b). We believe that this may
be related to relatively low levels of pAkt in CaOV3-
Akt1 (wt) cells despite high expression of total Akt.
The level of cell death for CaOV3 (vector) cells
was comparable to that of the parental CaOV3 cells
(data not shown). Oligosomal DNA fragmentation
and the percentage of hypodiploid cells were used
to measure apoptosis. Akt1 overexpression decreased
TRAIL-induced DNA fragmentation (Figure 2d) and
the percentage of apoptosis (Figure 2e) to a level equal
to untreated cells, suggesting that TRAIL-induced
apoptosis is inhibited by expression/activation of Akt.
Interestingly, despite showing resistance to TRAIL,
CaOV3-Akt-1 (wt) cells showed similar levels of
caspase-8 activity to control CaOV3 (vector) cells after
TRAIL treatment (Figure 2f). However, caspase-3
activity was signiﬁcantly lower in Akt 1-expressing
CaOV3 cells as compared with control cells. These
data suggest that Akt confers resistance to TRAIL-
induced apoptosis by interfering downstream of
caspase-8.
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OncogenePI3K and Akt inhibitors enhance TRAIL-induced
apoptosis in resistant cells
To further conﬁrm the role of Akt, we assessed whether
PI3K inhibitor LY294002 or Akt inhibitor blocked Akt
activation and enhanced TRAIL-sensitivity in resistant
cells. Treatment of SKOV3ip1 and COV2 cells with
LY294002 (5mM) for 90min strongly blocked Akt
phosphorylation (Figure 3a). Although we did not ﬁnd
any correlation between c-FLIPS or c-FLIPL protein
levels and TRAIL sensitivity (Figure 1e), we assessed the
effect of LY294002 on c-FLIPS or c-FLIPL expression
to ensure that Akt activity does not affect their
expression. Figure 3b shows no effect of PI3K inhibition
on c-FLIPS or c-FLIPL protein levels in SKOV3ip1
cells. Similarly, the levels of pAkt and total Akt were
not affected by TRAIL in SKOV3ip1 cells (Figure 3c).
Pre-incubation of SKOV3ip1 or COV2 cells with LY294002
(5mM) or Akt inhibitor (10mM) sensitized these cells to
TRAIL-induced apoptosis as shown by increased oligo-
somal DNA fragmentation (Figure 3d) and increased
rounded dead cells (Figure 3e) compared with controls.
Akt activation in human primary samples of EOC
correlated with decreased TRAIL sensitivity
To determine whether Akt activation is correlated with
decreased TRAIL sensitivity in clinical samples of EOC,
we obtained primary samples of tumor cells from
women having serous ovarian carcinoma. The sensitivity
of primary ovarian tumors cells to TRAIL was
determined by XTT assay as described previously
(Lane et al., 2004), and expressed as IC50. The relative
expression of pAkt in primary samples was assessed by
western blotting and expressed as fold increased relative
to pAkt levels in CaOV3 cells. pAkt levels in primary
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Figure 1 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance correlates with Akt activation in ovarian
cancer cells. Cell viability was assessed in four ovarian cancer cell lines by a short-term assay where cells were incubated with TRAIL
(100ng/ml) for 48h and viability was assessed by XTT assay (a), and by a long-term assay where cells were treated with TRAIL
(100ng/ml) or left untreated (control) for 2h and colonies were counted after 14 days (b). Apoptosis was measured by determining
oligosomal DNA fragementation (c) and the percentage of apoptosis (d) was measured as percentage of hypoploid cells assessed by
ﬂow cytometry analysis during exposure to TRAIL (100ng/ml) for 24h. Data shown are means±s.e.m. derived from three
independent experiments. (e) Expression/phosphorylation of Akt, FLIPL and FLIPS were analyzed by western blotting with
appropriate antibodies. Representative immunoblot from three independent experiements. *Po0.001.
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Oncogenetumor samples correlated well and positively with
increased TRAIL IC50, indicating that Akt activation
confers resistance to TRAIL in vivo (n¼12, Pearson’s
r¼0.950; Po0.0001).
TRAIL resistance is downstream of caspase-8 but
upstream of mitochondria
Analysis of caspase activation indicated that the pro-
caspases were processed and cleaved fragments of
caspase-8 (p43/41, p18) and caspase-9 (p35) was gener-
ated in TRAIL-sensitive OVCAR3 cells (Figure 4a).
The generation of active caspase-8 and caspase-3
fragments was conﬁrmed by measuring the cleavage
of caspase-8 and caspase-3 substrates in OVCAR3
cells (Figure 4b). In contrast, only partially processed
caspase-8 p43/41 fragments were detected in SKOV3ip1
and neither caspase-8 nor caspase-9 mature fragments
were detected. The measurement of caspase-8 activity
however, showed substantial caspase-8 substrate clea-
vage in SKOV3ip1 cells although to a lesser extend
relative to OVCAR3 cells (Figure 4b). This indicated
that caspase-8 is activated in SKOV3ip1 but probably at
a level which is too low to be detected by an immuno-
blot. Caspase-3 activity was not, however, detected in
SKOV3ip1 cells (Figure 4b). As binding of TRAIL to its
receptors causes recruitment of pro-caspase-8 at part
of the DISC, resulting in activation of caspase-8, we
immunoprecipitated the DISC in cells treated with
FLAG-tagged TRAIL. As shown in Figure 4c, pro-
caspase-8 was recruited and cleaved at the DISC in a
time-dependent manner in both sensitive and resistant
cells. Of note, recruitment and processing of pro-
caspase-8 at the DISC was not affected by LY294002
(Figure 4d). Similarly, caspase-8 activity in total cell
lysate of SKVO3ip1 cells was not inhibited by LY294002
(Figure 4e) indicating that Akt blockade occurs down-
stream of caspase-8.
Mitochondrial activation is an essential event for
efﬁcient TRAIL-induced apoptosis in EOC cells (Cuello
et al., 2004). We, therefore, examined the effect of
TRAIL on mitochondrial outer membrane permeabi-
lization and cytochrome c release in OVCAR3 and
SKOV3ip1 cells. Mitochondrial outer membrane per-
meabilization was assessed by the uptake of a lipophilic
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Oncogenecationic dye where red ﬂuorescence represents intact
mitochondria membrane and green ﬂuorescence repre-
sents apoptotic mitochondria. Treatment of OVCAR3
cells with TRAIL, increased the number of green-
labeled mitochondria (Figure 5a) and consequently the
percentage of apoptotic mitochondria as compared with
SKOV3ip1 cells (Figure 5b). Heavy membrane, enriched
in mitochondria and cytosolic fractions, were isolated
from OVCAR3 and SKOV3ip1 cells, after treatment
with TRAIL. Cytochrome c was detected in the cytosol
of OVCAR3 cells as early as 2h after TRAIL treatment
whereas cytochrome c was not detected in SKOV3ip1
even after 8h of TRAIL treatment (Figure 5c). These
results suggest the mitochondrial cell death pathway is
inhibited in resistant cells.
tBid is not detected in resistant cells
TRAIL-induced Bid cleavage generates a truncated
form of Bid (tBid) that promotes the insertion of Bax
into the mitochondrial outer membrane. As shown in
Figure 6a, TRAIL (100ng/ml) treatment resulted in a
reduction in full-length Bid and the appearance of tBid
overtime in sensitive cells but not in resistant cells
suggesting that Akt interfere with caspase-8-mediated
Bid cleavage. To further support this observation,
SKOV3ip1 and COV2 cells were pre-incubated with
LY204002 (5mM) in the presence or absence of TRAIL.
When TRAIL was combined with LY294002, there was
a reduction of full-length Bid, but we did not detect tBid
presumably, because the levels of tBid are too low to be
detected by immunoblot (Figure 6b). Overexpression of
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OncogeneAkt1 in CaOV3 cells prevented TRAIL-induced Bid
cleavage (Figure 6c). These results suggest that Akt
inhibits TRAIL-induced activation of the mitochondrial
cell death pathway by preventing the accumulation of
tBid at levels sufﬁcient to induce apoptosis.
Akt activation decreases Bid protein levels
We compared levels of Bid protein in our TRAIL-
sensitive and -resistant cell lines. The expression of Bid
was lower in resistant cells, both, at the protein and
transcriptional levels (Figures 7a and e). In contrast,
the expression of Bcl-2, Bcl-XL, Mcl-1 and Bax did
not correlate with TRAIL sensitivity as shown by
immunoblot (Supplementary Figure S1 online). We next
examined Bid expression in CaOV3-EV and CaOV3-
Akt1 cells. The levels of Bid protein and mRNA were
lower in Akt1 overexpressing cells relative to CaOV3-
vector cells (Figures 7b and f). When Akt activation was
inhibited by a PI3K-inhibitor, LY294002, in TRAIL-
resistant cells, Bid expression was increased (Figure 7c).
To further evaluate whether Akt inhibits Bid expression
at the transcriptional level, we carried out Bid qRT–
PCR at 2 and 6h after exposure of CaOV3 cells to EOC
ascites, which induce Akt activation within 30min (Lane
et al., 2010). As shown in Figure 7d, there was a decrease
in Bid mRNA expression at 2 and 6h. Taken together,
these data suggest that Akt inhibits TRAIL-induced
apoptosis by decreasing the expression of Bid.
Depletion of Bid inhibits TRAIL-induced apoptosis
We examined the effect of Bid depletion by RNA inter-
ference on TRAIL-induced apoptosis in TRAIL-sensitive
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OncogeneOVCAR3 cells. Knockdown of Bid by siRNAs decreased
the levels of Bid at 24 and 48h, whereas, the control
siRNA (siRNA Luc) did not affect Bid expression at
48h (Figure 8a). Bid depletion completely inhibited
TRAIL-induced cell death, as evident, by the same number
of colonies found in long-term assays in the presence or
absence of TRAIL (20ng/ml) (Figure 8b). Apoptosis was
also signiﬁcantly reduced, (Po0.001) as shown by further
limited oligosomal DNA fragmentation (Figure 8c) and
lower percentage of hypodiploid cells, in the presence of
Bid siRNA (Figure 8d). Consistent with these observations,
we were unable to detect tBid by immunoblot in Bid
siRNA-transfected cells whereas tBid was detected with the
control siRNA (Figure 8e). We tried to perform similar
experiments in CaOV3 cells, but were not able to obtain
consistent downregulation of Bid in these cells. This was
probably related to the fact that CaOV3 cells are relatively
resistant to siRNA transfection, as we did not achieve
efﬁcient transfection with the control ﬂuorescent siRNA
(siRNA Luc), either. In all, our data suggest Bid down-
regulation increased the resistance of OVCAR3 cells to
TRAIL-induced apoptosis.
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OncogeneBid overexpression promotes TRAIL-induced apoptosis
in resistant cells
The requirement of Bid for TRAIL-induced apoptosis
was conﬁrmed by comparing the effects of stably
expressing green ﬂuorescent protein (GFP)-tagged Bid
and GFP only in SKOV3ip1 cells. TRAIL treatment
induced the cleavage of GFP-tagged Bid as shown by
immunoblot (Figure 9a). However, the cleavage of
endogenous Bid could not be detected as previously
shown (Figure 6). TRAIL treatment also induced
greater apoptosis in SKOV3ip cells overexpressing Bid
compared with control cells (25.1±1.3 vs 12.7±0.8%,
Figure 9b). Interestingly, the addition of LY294002
enhanced TRAIL-induced apoptosis in Bid-expressing
SKOV3ip1 cells (35±1.5 vs 25.1±1.3%) suggesting that
the inhibition of Akt phosphorylation enhanced Bid
cleavage or that it alleviate a downstream blockade. The
basal level of apoptosis in Bid-expressing SKOV3ip1
was unaffected by LY294002.
TRAIL resistance is not affected by XIAP
downregulation
Bid and XIAP are substrates for caspase-3. In the
presence of activated caspase-3, the full-length 53kDa
XIAP protein is depleted and concomitant generation of
a 30kDa fragment occurs (Deveraux et al., 1999).
XIAP, the most potent caspase inhibitor of the IAP
family, has been shown to regulate drug- and death
receptor-induced apoptosis in EOC cells (Asselin et al.,
2001; Lane et al., 2006). XIAP binds to the active form
of caspase-3, but not to pro-caspase-3, and promotes its
proteasomal degradation (Grifﬁth et al., 1998; Deveraux
et al., 1999; Lane et al., 2006). As XIAP regulates
caspase-3 activity, it may also affect Bid cleavage. We
therefore compared the levels of XIAP expression in
sensitive and resistant cells and in CaOV3-Akt1 (wt)
cells. There was no difference in XIAP expression
between the cell lines (Figures 10a and b). As expected,
XIAP was cleaved in TRAIL-sensitive CaOV3 cells
but not in SKOV3ip1 cells (Figure 10c). To evaluate
more speciﬁcally its contribution to TRAIL resistance,
we downregulated XIAP expression with siRNA in
SKOV3ip1 cells (Figure 10d). This treatment efﬁciently
abolished XIAP expression but did not substantially
sensitize cells to TRAIL (Figure 10e). In addition, XIAP
downregulation had no effect on the cleavage of Bid and
TRAIL-induced caspase-3 activation remained unaffected
(Figure 10f). These data suggest XIAP do not signiﬁcantly
contribute to TRAIL resistance in SKOV3ip1 cells and
thus,support our concept that Akt interfere with Bid
processing upstream of the mitochondria.
Discussion
In this study, we show that the PI3K/Akt signaling
pathway regulates TRAIL-induced apoptosis in EOC
cells. Akt activation mediates TRAIL resistance by
decreasing Bid expression and possibly by inhibiting its
cleavage. We also showed that Akt activation correlates
with decreased TRAIL sensitivity in primary cultures of
ovarian carcinoma suggesting the importance of Akt
activation in clinical setting.
Because of the potential of TRAIL in antitumor
treatment, considerable effort is being directed at
understanding the determinant of TRAIL resistance
in cancer cells. In addition, many tumor cells, and in
particular EOC cells, appear, at least in vitro, resistant
to TRAIL-induced apoptosis (Lane et al., 2004).
Activation of the PI3K/Akt pathway is common in
ovarian carcinoma (Bast et al., 2009). There have been
several reports showing the role of Akt in EOC drug
resistance (Page et al., 2000; Hu et al., 2002; Fraser
et al., 2003; Westfall and Skinner, 2005; Yang et al.,
2006; Mabuchi et al., 2007). However, the role of Akt
in promoting survival against death receptor-induced
apoptosis in EOC cells has not been clearly deﬁned.
A few reports suggested a role for the PI3K/Akt
pathway in mediating TRAIL resistance. In two of
these studies, Akt activation mediated by EOC ascites
or serum from ovarian cancer patients inhibited
TRAIL-induced apoptosis (Kang et al., 2004; Lane
et al., 2007). Conversely, the inhibition of Akt phos-
phorylation in TRAIL-resistant SKOV3 cells enhanced
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OncogeneTRAIL-induced apoptosis (Kim and Lee, 2005; Lane
et al., 2008). Taken together, these studies suggested
a role for Akt in the regulation of TRAIL-induced
apoptosis. This study shows that overexpression of
Akt1 in TRAIL-sensitive EOC cells, CaOV3 enhanced
resistance to TRAIL whereas inhibition of PI3K or Akt
decreased resistance to TRAIL-mediated cell death.
Therefore, our data clearly established that the PI3K/Akt
pathway has an important role in regulating TRAIL-
induced apoptosis in EOC cells. Intrinsic resistance
to TRAIL among ovarian cancer cells appears to be
mediated, at least in part, by activation of this pathway.
The clinical relevance of this observation was conﬁrmed in
primary cultures of tumor obtained from women suffering
with advanced ovarian carcinoma. We established a statis-
tical correlation between the levels of Akt-phosphorylation
and TRAIL-IC50 in the primary cultures.
The antiapoptotic effect of Akt is believed to occur
downstream of caspase-8 activation. Similarly, we found
that Akt activation or its inhibition did not interfere
with the recruitment and processing of pro-caspase-8
at the DISC. Activation of Akt inhibits apoptosis
before mitochondrial cytochrome c release (Kandel
and Hay, 1999). To promote release of cytochrome c,
tBid translocates to the mitochondria where, in concert
with pore-forming Bax and Bak proteins, it activates
the mitochondria (Luo et al., 1998). Although it is well-
established that Akt may function at the mitochondria
by phosphorylating Bad which prevents its interaction
with antiapoptotic proteins Bcl-2/Bcl-XL, there have
been a number of reports, suggesting that Akt acts
upstream of the mitochondria, although the site of
action of Akt in the apoptotic cascade was not certain.
In one study, Akt activation did not prevent Bid
cleavage but inhibited Bak oligomerization and Bax
activation, which are critical events in tBid-induced
apoptosis (Majewski et al., 2004). In another report,
although the authors could not identify the precise
mechanism by which tBid was unable to activate Bax or
Bak in TRAIL-resistant colon cancer cells despite the
fact the tBid effectively translocated to the mitochondria
(Ndozangue-Touriguine et al., 2008). In this study, we
showed that Akt activation prevents the accumulation
of caspase-8-induced tBid in TRAIL-resistant EOC
cells, as shown by the observation that Akt over-
expression in TRAIL-sensitive EOC cells prevents the
detection of tBid. The fact that overexpression of Bid in
SKOV3ip1 could induce apoptosis suggests that there
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Oncogenewas simply insufﬁcient production of endogenous tBid
after TRAIL treatment to directly activate BAK in these
cells. The mechanism by which Akt interferes with the
accumulation of tBid is not certain. Bid can be phospho-
rylated by casein kinase II leading to resistance to
cleavage by caspase-8 and resistance to TRAIL-induced
apoptosis (Desagher et al, 2001; Izeradjene et al., 2005).
However, analyses of Bid phosphorylation by immuno-
blot in CaOV3 (vector) and CaOV3-Akt1 (wt), showed
that ectopic Akt1 expression did not affect Bid phospho-
rylation (N. Goncharenko-Khaider, unpublished data)
suggesting that Akt pathway does not block Bid cleavage
by interfering with its phosphorylation. In addition,
TRAIL-induced apoptosis in resistant EOC cells was not
affected by the chemical inhibition of casein kinase II
with apigenin or with emodin (lane D, unpublished
data). It seems unlikely therefore that Akt affects Bid
cleavage by interfering with Bid phosphorylation or by
modulating the activity of casein kinase II. We cannot
rule out the possibility that Akt does not directly interfere
with Bid cleavage, but instead regulates tBid degradation
or acts downstream of Bid to antagonize tBid activity at
the mitochondria.
Our study reveals the critical importance of Bid
expression levels to regulate TRAIL-induced apoptosis.
We provide evidence that Akt transcriptionally regu-
lates the expression of Bid. Firstly, EOC resistant-cells
express lower levels of Bid protein (Figure 7). Secondly,
PI3K inhibition increases Bid protein levels (Figure 7c).
Finally, Akt activation increases mRNA Bid levels.
The depletion of Bid by siRNAs signiﬁcantly decreased
TRAIL-induced apoptosis and prevented the detection
of tBid in sensitive cells. Conversely, Bid overexpression
in resistant cells increased apoptosis and led to tagged-
Bid cleavage. Therefore, the Akt-mediated downregula-
tion of Bid contributes to decreasing the sensitivity of
EOC cells to TRAIL-induced apoptosis.
The antiapoptotic protein Mcl-1, a member of Bcl-2
family, has emerged as an important regulator of
TRAIL sensitivity (Kim et al., 2008). Mcl-1 can bind
to pro-apoptotic BH3-only proteins, such as Bim, Puma,
and Bak, thereby inhibiting the activation of the
mitochondria (Cheng et al., 2005). We have previously
shown that ascites-induced Akt activation in CaOV3
cells does not affect the levels of pro-apoptotic proteins
Bax and Bak and antiapoptotic proteins Bcl-2 and
Bcl-XL (Lane et al., 2007). Consistent with these results,
we showed in this study that expression of Mcl-1, Bcl-2
and Bcl-XL did not correlate with resistance to TRAIL.
Previous reports have suggested that in sensitive
CaOV3 and HeLa cells, inhibition of TRAIL-induced
apoptosis by Akt activation occurs by an upregulation
of c-FLIP expression (Kang et al.,2 0 0 4 ;L a n eet al., 2007).
Interestingly, we showed here that c-FLIP expression
did not correlate with TRAIL sensitivity and c-FLIP
expression was not affected by Akt inhibition in resistant
cells. These data suggest that the mechanism by which
Akt blocks the TRAIL signaling cascade may differ
in sensitive vs resistant EOC cells. Akt activation in
sensitive EOC cells may involve a dual resistance to
TRAIL: a block at the DISC level through ascites-
mediated upregulation of c-FLIPS (Lane et al., 2007) and
a block at the Bid level because we showed that Akt1
overexpression in sensitive CaOV3 cells decreased Bid
protein levels. In some context, XIAP has been shown to
be a critical regulator of death receptor-induced apop-
tosis (Jost et al., 2009). Although the basal levels of
XIAP were mostly comparable between sensitive and
resistant cell lines, TRAIL treatment induced the
cleavage of XIAP in sensitive cells, indicating that it is
a consequence of cell death. However, the depletion of
XIAP by siRNAs did not affect TRAIL-induced cell
death, Bid levels and caspase-3 activation in SKOV3ip1
cells, ruling out a prominent role for XIAP in mediating
TRAIL resistance.
In summary, we propose that binding of TRAIL to its
cognate receptors induces caspase-8 activation at the
DISC in both sensitive and resistant cells. In resistant
cells, Akt activation decreases Bid protein levels and
possibly interferes with its cleavage. The level of tBid
generated is therefore below a threshold that is insufﬁ-
cient to trigger Bid-mediated Bax or Bak activation.
The lack of efﬁcient mitochondrial activation prevents
the mitochondrial feedback loop required to fully activate
caspase-8 in the cytosol. However, the low level of Akt
activation in sensitive cells is insufﬁcient to decrease Bid
levels or to prevent tBid accumulation. In these conditions
the amount of tBid produced is sufﬁcient to fully activate
the formation of Bax/Bak complexes resulting in activa-
tion of the mitochondria.
Materials and methods
Ovarian cancer tumor samples and cell culture
Tumor cells were isolated from EOC ascites ﬂuids as described
previously (Lane et al., 2004). Informed consent was obtained
from all participants for this institutional review board-
approved protocol. All samples were supplied by the Tumor
Bank of the Re ´ seau de Recherche en Cancer du Fond de
Recherche en Sante ´ du Que ´ bec, Canada. All tumor cell
samples were used at low passage (o10). The human EOC cell
line CaOV3 and OVCAR3 were obtained from the American
Type Culture Collection (Manassas, VA, USA) and main-
tained in RPMI-1640 (Wisent, St-Bruno, QC, Canada)
supplemented with 10% fetal bovine serum and insulin
(10mg/l). CaOV3 cells were cultured in Dulbecco’s modiﬁed
Eagle medium/F12 (Wisent) supplemented with 10% fetal
bovine serum and 2mM glutamine. COV2 cells were derived
from ascetic ﬂuids obtained from a patient suffering with a
primary stage III serous ovarian carcinoma and were main-
tained in Dulbecco’s modiﬁed Eagle medium/F12 (Wisent)
supplemented with 20% fetal bovine serum. The SKOV3ip1
human EOC cell line was kindly provided by J. Price (MD
Anderson Cancer Center, Houston, TX, USA) and maintained
in Dulbecco’s modiﬁed Eagle medium/F12 supplemented with
10% fetal bovine serum (Wisent).
Reagents
TRAIL was purchased from PeproTech. (Rocky Hill, NJ, USA).
HRP-conjugated anti-mouse and -rabbit antibodies were purchased
from Cell Signaling (Pickering, ON, Canada). Akt, caspase-3,
caspase-9, COX IV, Bid and cytochrome c antibodies were also
purchased from Cell Signaling. Antibodies for phospho-Akt
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Oncogene(Ser-473 were obtained from Invitrogen (Biosource, Burlington,
ON, Canada). Caspase-8 antibodies were obtained from R&D
Systems (Minneapolis, MN, USA). Phenazine methosulfate and
anti-tubulin antibody were obtained from Sigma. XTT reagents
were from Invitrogen (Burlington, ON, Canada). LY294002
and Akt-speciﬁc inhibitor 1L-6-hydroxymethyl-chiro-inositol
2(R)-2-O-methyl-3-O-octadecylcarbonate were purchased from
Sigma. Lipofectamine 2000 was purchased from Sigma (Oakville,
ON, Canada).
Retroviral preparation and transduction efﬁciency
The pLPCXL retroviral vector construct endocing wildtype
(wt) Akt1 was kindly provided by N. Rivard (University of
Sherbrooke, Que ´ bec, Canada). Retroviral particles were
generated by transfecting 293T cells with pLPCXL-Akt1,
pVPack-VSV-G and pVPack-GP (Invitrogen) and used to
infect CaOV3 cells. Pools of productively infected cells
obtained by selection with puromycin (0,4 mg/ml) for 10 days
were used for further analysis. In the case of stable expression
of Bid, SKOV3ip1 cells were transfected with either pEGFPN1
vector (Clontech, Mountain view, CA, USA) or pEGFPN1
containing full-length Bid (cloned in EcoR1 site), selected in
G-418 (1mg/ml) for 10 days, and then used as a pooled.
Quantitative RT–PCR
Total RNA was extracted from CaOV3 cells using TRIzol
reagent according to the manufacturer’s protocol and sub-
jected to reverse transcription using Promega (Madison, WI,
USA) reverse transcriptase enzyme. The integrity of the cDNA
was assessed by SRBR-base quantitative PCR, done on four
housekeeping genes: MRPL19, PUM1, GAPDH and actin.
Each sample was normalized to housekeeping gene levels.
Primer sequences are available on request. Cycle conditions for
all PCRs were as follows: an initial incubation of 2min at
951C followed by 35 cycles at 941C for 30s, 551C for 30s,
721C for 60s. The ampliﬁcation was carried out by a 2-min
incubation at 721C. PCR products quantiﬁcation was
performed as previously described (Klinck et al., 2008).
Cell viability assays
Short-term cell viability in the presence or absence of TRAIL
was determined by XTT assay. Brieﬂy, cells were plated at
20000 cells/well in 96-well plates in complete medium. The
next day, cells (conﬂuence 60–70%) were treated with human
TRAIL and incubated for 48h. At the termination of the
experiment, the culture media was removed and a mixture of
phosphate-buffered saline and fresh media (without phenol
red) containing phenazine methosulfate and XTT was added
and kept for 30min at room temperature. The absorbance was
determined using a microplate reader at 450nm (TecanSunrise,
NC, USA). The percentage of cell survival was deﬁned as the
relative absorbance of untreated versus TRAIL-treated cells.
For clonogenic survival assays, cells were plated in six-well
tissue culture plates in standard medium. The next day, cells
were treated with TRAIL (20–100ng/ml) for 2h, followed by
several washes with standard medium. Then, cells were
incubated in standard medium for 14 days. Cells were ﬁxed
and stained with crystal violet. The number of colonies,
consisting of 425 cells, in triplicate was counted.
Apoptosis and caspase assays
Caspase-3 and caspase-8 ﬂuorogenic protease assays were
performed according the manufacturer’s protocol (R&D
Systems). In brief, 3 10
6 cells were lysed in 250ml of cell
lysis buffer, and total cell lysates were incubated with 50mM of
DEVD-AFC (caspase-3) or IETD-AFC (caspase-8) substrate
for 1h at 371C. Caspase-3 and caspase-8 activities were
measured on a Versa Fluor ﬂuoremeter (BioRad, Hercules,
CA, USA). Protein concentration of the lysates was measured
with Bio-Rad protein assay kit according to the manufac-
turer’s recommendations. The release of nucleosomal DNA
into the cytoplasm as a measure of apoptosis was determined
using the Cell Death Detection ELISA Kit (Roche, Laval,
Que ´ bec, Canada) according to the manufacturer’s instruction.
The absorbance was determined using a microplate reader at
410nm (TecanSunrise). Propidium iodide staining for DNA
fragmentation was done by ﬁxing cells and staining them with
propidium iodide for DNA analysis content as previously
described (Lane et al., 2006). A total of 10000 events were
analyzed by ﬂow cytometry and the percentage of hypodiploid
cells was measured.
Western blot analysis
Cells were harvested and washed with ice-cold phosphate-
buffered saline. Whole cell extracts were prepared in lysing
buffer (glycerol 10%, Triton X-100 1%, TRIS 10mM pH 7.4,
NaCl 100mM, EGTA 1mM, EDTA 1mM,N a 4P2O7 20mM,
NaF 1mM,N a 3VO4 2m M and SDS 0.1%) containing protease
inhibitors (0.1mM AEBSF, 5mg/ml pepstatin, 0.5mg/ml
leupeptin and 2mg/ml aprotinin) and cytosolic proteins were
separated by 12% SDS–PAGE gels. Lysates for phosphory-
lated proteins were prepared in the presence of phosphatase
inhibitors (100mM sodium ﬂuoride, 100mM sodium pyropho-
sphate and 250mM sodium orthovanadate). Proteins were
transferred to PVDF membranes (Roche) by electroblotting,
and immunoblot analysis was performed as previously
described (Lane et al., 2006). All primary antibodies were
incubated overnight at 41C. Proteins were visualized by
enhanced chemiluminescence (GE Healthcare, Baie d’Urfe ´ ,
Que ´ bec, Canada).
Knockdown of Bid and XIAP
The Fluorescein-labeled Luciferase GL2 duplex was used as a
control, the Bid siRNA was obtained from Dharmacon Research
(Lafayette, CO, USA) and XIAP siRNA (Signal Silence XIAP
siRNA) were purchased from Cell Signaling. Cells (6 10
4)w e r e
seeded in six-well plates and allowed to adhere for 24h. Cells
(50% conﬂuent) were transfected with a mixture containing
LipoFectamine 2000 (Invitrogen Life Technologies, Burlington,
ON, Canada), optiMEM (Invitrogen) and Bid siRNA (10mM)o r
XIAP siRNA (25mM). The siRNAs/oligofectamine mixture was
then added to the media of six-well plates containing cells.
Cells were incubated for 4–6h at 371Ci naC O 2 incubator and
a medium containing fetal bovine serum was then added to it.
After 48h, TRAIL was added and cells were further incubated
for another 48h after which XTT assays were performed.
For western blotting, the cells were lysed for 24 or 48h post-
transfection and total cell lysates were analyzed by immunoblot.
Statistical analysis
Statistical comparisons between two groups were performed
using the Student’s t-test and with ANOVA when comparing
the data with more than two treatments groups. Statistical
signiﬁcance was indicated by Po0.05. The strength of the
association between TRAIL IC50 and Akt phosphorylation
levels in primary tumor samples was measured using Pearson’s
correlation coefﬁcient parametric approach.
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